CVT Announces Canadian Patent Approval For Parathyroid Hypertensive Factor.

Business Editors

EDMONTON, Alberta--(BUSINESS WIRE)--Aug. 10, 2000

CV Technologies, Inc. (CDNX:CVQ.) today announced that the Canadian Patent Office has issued a Notice of Allowance for CVT's Parathyroid Hypertensive Factor (PHF) patent application.

PHF, a hormone discovered by CVT scientists, is a key factor in intracellular calcium dysregulation and is particularly associated with type 2 diabetes and hypertension, which affects nearly one quarter of the world's population. PHF is useful in the assessment of patients with diseases involving intracellular calcium dysregulation and in the study of other diseases in which intracellular calcium dysfunction is involved. The presence of this factor in patients indicates novel therapeutic treatments.

The PHF Patent strengthens the strategic alliance announced in April between CVT and Axis-Shield Diagnostics of Dundee, Scotland to license CVT's in vitro PHF Technology. Axis-Shield, which is currently developing the test kit, is a recognized international leader in the development and supply of in vitro diagnostics and possesses particular expertise in the development of novel blood tests for cardiovascular-disease-risk testing.

"The ultimate strength of CVT is its ability to develop leading-edge technology capable of dramatically improving the efficacy and consistency of natural health products," said Jim Bruce, president and CEO. "Ensuring the protection of CVT's substantial intellectual property through the patent process is key to the Company expanding its leadership position in the natural health and biopharmaceutical products industry."

This patent for CVT's PHF is the latest to be issued for PHF, joining six U.S. and five international patents.

Utilizing the ChemBioPrint(TM) platform, CVT has commercialized six health supplement products under its HerbTech(TM) brand that are marketed through Safeway Stores, the real Canadian Superstores, Whole Foods Markets and many other health food stores throughout North America. The Company has over 20 additional health supplement products in its product pipeline to be introduced over the next three to four years. The Company's pharmaceutical drug candidate to alleviate colds and flu, developed under the ChemBioPrint(TM) platform, is currently being tested under U.S. FDA Investigational New Drug (IND) status in a phase II clinical trial at the Eastern Virginia Medical School. The Company plans to utilize the ChemBioPrint(TM) platform to develop an extensive new range of commercial products and offer analytical testing services to the health industry on a contractual basis.

About CV Technologies

CV Technologies (CVT) is an international science and technology Company which has developed and commercialized proprietary technology to identify, extract, and biologically standardize natural mixtures which deliver health benefits. CVT's research facility is located in Edmonton, Alberta. CVT has a staff of 40 people including 12 with Ph.D.'s and 2 M.D.'s. The Company maintains two full-scale laboratories and has access to 18 satellite facilities including offices in Boulder, Colorado and Hong Kong.

Utilizing the Company's ChemBioPrint(TM) technology, CVT scientists obtain specific chemical and biological profiles of natural mixtures, in addition to determining their mechanisms of action and optimal dosages. The result is the development of precise operating procedures for commercial production. All CVT products are certified effective, safe, biologically active, and consistent, batch-to-batch.

CV Technologies markets products in Canada under its HerbTech(R) brand name and supplies proprietary ingredients to national and international markets. The Company currently holds 19 patents, which includes 12 U.S. patents. An additional 36 patents are pending worldwide. Three Patent Cooperation Treaty applications have been filed.

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of preclinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products and other risks detailed from time to time in the Company's filings with Canadian securities authorities.

"The Canadian Venture Exchange has neither approved nor disapproved the information contained herein."